MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Who May Qualify: - Documented diagnosis of ATTR amyloidosis with cardiomyopathy - Medical history of heart failure (HF) - Symptoms of HF are optimally managed and clinically stable within 28 days prior to administration of study intervention - Screening NT-proBNP, a blood marker of HF severity, greater than or equal to 600 pg/mL and less than 10,000 pg/mL Who Should NOT Join This Trial: - New York Heart Association (NYHA) Class IV HF - Polyneuropathy Disability score of IV (confined to wheelchair or bed) - Has hepatitis B, hepatitis C or human weakened immune system virus (HIV) infection - History of active malignancy within 3 years prior to screening - RNA silencer therapy (patisiran, inotersen and/or eplontersen) within 12 months prior to dosing. Any prior vutrisiran use is not allowed - Initiation of tafamidis or acoramidis within 56 days prior to study dosing - Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m\^2 - History of liver disease - Uncontrolled blood pressure - Unable or unwilling to take vitamin A supplementation for the duration of the study Always talk to your doctor about whether this trial is right for you.